Aflibercept

• Description:

  Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease[1][2][3].

• Product Name Alternative:

  VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

• UNSPSC:

  12352203

• Target:

  VEGFR

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/aflibercept.html

• Purity:

  97.90

• Solubility:

  10 mM in DMSO

• Smiles:

  [Aflibercept]

• Molecular Weight:

  (96.9 kDa)

• References & Citations:

  [1]Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014 Oct;98 (10) :1448-52.|[2]Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor) -Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52 (8) :2637-2648.|[3]Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin. 2021 Sep;42 (9) :1437-1448.

• Shipping Conditions:

  Isolate blue ice and the product with bubble pack to avoid direct contact

• Storage Conditions:

  Store at 4°C for 2 years, do not freeze

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Launched

• CAS Number:

  [862111-32-8]